0001104659-21-076218.txt : 20210603 0001104659-21-076218.hdr.sgml : 20210603 20210603115312 ACCESSION NUMBER: 0001104659-21-076218 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210602 FILED AS OF DATE: 20210603 DATE AS OF CHANGE: 20210603 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Raykov Rosty CENTRAL INDEX KEY: 0001468316 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32295 FILM NUMBER: 21991759 MAIL ADDRESS: STREET 1: C/O ADHEREX TECHNOLOGIES INC. STREET 2: 4620 CREEKSTONE DRIVE, SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FENNEC PHARMACEUTICALS INC. CENTRAL INDEX KEY: 0001211583 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: PO BOX 13628 STREET 2: 68 TW ALEXANDER DRIVE CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 BUSINESS PHONE: (919) 636-4530 MAIL ADDRESS: STREET 1: PO BOX 13628 STREET 2: 68 TW ALEXANDER DRIVE CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 FORMER COMPANY: FORMER CONFORMED NAME: FENNEC PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20140903 FORMER COMPANY: FORMER CONFORMED NAME: ADHEREX TECHNOLOGIES INC DATE OF NAME CHANGE: 20021223 4 1 tm2118436-1_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-06-02 0 0001211583 FENNEC PHARMACEUTICALS INC. FENC 0001468316 Raykov Rosty 68 TW ALEXANDER DRIVE, PO BOX 13628 DURHAM NC 27709 1 1 0 0 Chief Executive Officer Stock Option (right to buy) 7.53 2021-06-02 4 A 0 250000 0 A 2031-06-02 Common Shares 250000 250000 D On June 2, 2021, Rostislav Raykov was granted an incentive stock option to purchase 250,000 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan. 1/3 of the shares subject to this option shall vest immediately and may be exercised as of June 2, 2022 (the "Vesting Commencement Date"). 1/24 of the shares subject to this option shall vest immediately and may be exercised as of the last day of each month following the Vesting Commencement Date. As of May 31, 2024 and thereafter, 100% of the total number of shares subject to this option shall be vested. /s/ Rostislav Raykov, Chief Executive Officer 2021-06-03